This is a single center, randomized, controlled phase 2b, conversion trial. This protocol has
been developed to answer the question: Can patients be safely converted from monthly
belatacept IV infusions to abatacept subcutaneous injections without a decrease in kidney
function.The primary objective will be the difference in estimated GFR (eGFR) for abatacept
and belatacept groups using a monthly repeated measures model between randomization and 12
months.